STOCK TITAN

Amaero (AMRO) 424B Filings

AMRO NASDAQ

Here are the 424B prospectus supplements from Amaero Inc. (AMRO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 424B covers the supplement that carries the terms of a priced offering, so if you follow AMRO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMRO filings page.

Rhea-AI Summary

Amaero Inc. is selling 4,705,883 shares of common stock at $4.25 per share in its U.S. IPO. It estimates net proceeds of approximately $15.7 million, with up to approximately $10.0 million for capital equipment over the next 12 months and the remainder for general corporate purposes, including working capital, operating expenses and research and development. Amaero has approval to list its common stock on the Nasdaq Capital Market under AMRO; its CDIs are listed on the ASX under 3DA.

Preliminary, unaudited revenue for the three months ended September 30, 2026 is estimated at $3.96–$4.12 million, versus $3.05 million a year earlier; net loss attributable to stockholders is estimated at $9.07–$9.50 million, versus $4.096 million. Management says that, if the offering is completed, proceeds and cash are expected to fund operations and capital spending into the second quarter of 2027. It also states that the proceeds will not alleviate substantial doubt about the company’s ability to continue as a going concern for at least 12 months after the offering and that additional financing will be required. Amaero identified a material weakness in internal control over financial reporting.